Ondine Biomedical Inc. presented detailed results from its US Phase 2 BENEFIT-aPDT clinical trial to the 33rd European Congress of Clinical Microbiology and Infectious Diseases in Copenhagen, Denmark.
Ondine Biomedical’s Nasal Photodisinfection Cuts Surgical Site Infections by 66% Read More »
Nordic Nanovector ASA announces that full results from its Phase 2 clinical trials of Betalutin® in resistant/refractory indolent non-Hodgkin’s lymphoma have been published at EudraCT, the European Union Drug Regulating Authorities Clinical Trials Database of the European Union.
Biophytis SA announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting.
Biophytis: Results of the Combined General Meeting on April 17, 2023 Read More »
Biophytis SA announces its financial results for the year ended December 31, 2022, and provides updates on key perspectives for 2023.
Biophytis Announces 2022 Financial Results and 2023 Perspectives Read More »
Data of InnoCare’s robust oncology pipelines were presented at the 2023 American Association for Cancer Research Annual Meeting.
Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting Read More »
BerGenBio ASA announced that it presented data linking AXL activation to STK11 loss of function in Non-Small Cell Lung Cancer in an abstract titled, AXL as a Therapeutic Target in STK11 mutant NSCLC, at the American Association for Cancer Research Annual Meeting 2023.
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR Read More »
AbbVie announced that the U.S. Food and Drug Administration has approved expanding the indication of QULIPTA® for the preventive treatment of migraine in adults.
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine Read More »
Carbios has accelerated its enzyme screening process with a microfluidic technology developed in partnership with the Paul Pascal Research Centre.
Lucid Diagnostics Inc. announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference Read More »
Transgene and NEC Corporation announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research Annual Meeting in Orlando, Florida.
